Patent FR-2910322-B1 (FR)
Inventor: YVIN JEAN CLAUDE
IPC: A61K31/702
Filed: 2006-12-22
Granted: 2009-10-30
Abstract: The use of oligosaccharides (I) and (II), i.e. oligo-beta -glucan-(1,3)-mannose, -mannitol, -glucose and -glucitol compounds and their 4-deoxy derivatives, as medicaments for treating tumor, cancer, viral, bacterial, fungal, immune system, autoimmune or immunostimulation deficiency-associated diseases is new. Some compounds (I) and (II) (i.e. the mannose and mannitol derivatives) are new, as are various intermediates. The use of oligosaccharides of formulae (I) and (II) is claimed in the preparation of a medicament for treating tumor, cancer, viral, bacterial, fungal, immune system, autoimmune or immunostimulation deficiency-associated diseases in humans and warm-blooded animals. R 1H or OH; n : 2-10 (preferably 2-7, especially 3-5). Independent claims are included for: (1) oligo-beta -glucan-(1,3)-mannose (I') and oligo-beta -glucan-(1,3)-mannitol compounds (II') (including 4-deoxy derivatives), of formulae (I; terminal 2-OH in beta -configuration) and (II; terminal 2-OH in beta -configuration) respectively, as new compounds; (2) the preparation of (I') and (II'); and (3) new intermediate saccharide and oligosaccharide compound intermediates of formulae (III) - (VI). p : 0-9 (preferably 0-6, especially 2-4); R 2H, allyl, methylnaphthyl, benzyl, p-methoxybenzyl, COCH 2Cl, COCH 2Br or COCH 2I; or R 3, R 4, R 3', R 4' : benzyl (Bn), chlorobenzyl, nitrobenzyl, allyl, triarylmethyl, trialkylsilyl (e.g. SiEt 3, Si(CHMe 2) 3or Si(Me) 2tBu) or ester group (e.g. COMe, COCH 2Cl, COPh or pivaloyl); or R 3+ R 4, R 3'+ R 4' : CHMe, CMe 2, C(CF 3) 2, 5-7C cycloalkylidene, butylidene, 1-tert. butylethylidene, benzylidene, methoxybenzylidene or 1-phenylbenzylidene; R 5H, levinoyl (preferred), COMe, COCH 2Cl, fluorenylmethoxycarbonyl or trialkylsilyl (e.g. SiEt 3, Si(CHMe 2) 3or Si(Me) 2tBu); provided that R 3, R 4, R 3', R 4'are all different from R 5; R 7ester group, specifically COMe, COPh (preferred) or pivaloyl; R 8group orthogonal to all the other protecting groups, selected from benzyl (preferred), 2-methylnaphthyl (NAP), p-methoxybenzyl, p-methoxyphenyl and allyl; R 8benzyl; R 9OR 8or X; X : halogen. [Image] [Image] [Image] ACTIVITY : Cytostatic; Virucide; Antibacterial; Fungicide; Immunosuppressant; Immunostimulant; Immunomodulator. MECHANISM OF ACTION : Specific ligand for macrophage and leukocyte surface receptors; Immunocompetent cell stimulant; NK cell, T-lymphocyte and nuclear factor kappa-B activator; Phagocytosis modulator; Cytokine secretion modulator; Oxidizing species production modulator. In tests in Balb/c mice, beta -D-glucopyranosyl-(1-3)-beta -D-glucopyranosyl-(1-3)-beta -D-glucopyranosyl-(1-3)-beta -D-glucopyranosyl-(1-3)-beta -D-glucopyranosyl-(1-3)-beta -D-mannopyranose (Ia) was injected intraperitoneally at a dose of 100 mu g; peripheral blood samples were taken after 24 hours; and 2-hydroxyethyl methacrylate copolymer particle phagocytosis tests were carried out. The degree of phagocytosis was ca. 45% in both monocytes and granulocytes, compared with ca. 30% and 20% in monocytes and granulocytes respectively for saline-treated controls.